JPS58174317A - ジベンゾシクロヘプタジエンとコデルゴクリンを含有する薬学的組成物 - Google Patents

ジベンゾシクロヘプタジエンとコデルゴクリンを含有する薬学的組成物

Info

Publication number: JPS58174317A
Authority: JP; Japan
Prior art keywords: active agent; depression; preparation according; activator; treatment
Prior art date: 1982-03-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP58044528A

Other languages

English (en)

Japanese (ja)

Inventor

ロバ−ト・ダブリユ−・グリフイス

ジヤツク・シンガ−

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sandoz AG

Original Assignee

Sandoz AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-03-22

Filing date

1983-03-18

Publication date

1983-10-13

1983-03-18 Application filed by Sandoz AG filed Critical Sandoz AG

1983-10-13 Publication of JPS58174317A publication Critical patent/JPS58174317A/ja

Status Pending legal-status Critical Current

Links

239000008194 pharmaceutical composition Substances 0.000 title description 2
PJQCANLCUDUPRF-UHFFFAOYSA-N dibenzocycloheptene Chemical compound C1CC2=CC=CC=C2CC2=CC=CC=C12 PJQCANLCUDUPRF-UHFFFAOYSA-N 0.000 title 1
239000013543 active substance Substances 0.000 claims description 18
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 10
239000000935 antidepressant agent Substances 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
208000024827 Alzheimer disease Diseases 0.000 claims description 6
206010039966 Senile dementia Diseases 0.000 claims description 6
239000012190 activator Substances 0.000 claims description 6
230000001430 anti-depressive effect Effects 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 5
239000001257 hydrogen Substances 0.000 claims description 5
238000000034 method Methods 0.000 claims description 5
239000012458 free base Substances 0.000 claims description 4
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
125000001246 bromo group Chemical group Br* 0.000 claims description 3
125000001309 chloro group Chemical group Cl* 0.000 claims description 3
238000009472 formulation Methods 0.000 claims description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
102000018779 Replication Protein C Human genes 0.000 claims 1
108010027647 Replication Protein C Proteins 0.000 claims 1
150000002431 hydrogen Chemical class 0.000 claims 1
239000002775 capsule Substances 0.000 description 7
230000000694 effects Effects 0.000 description 7
229940005513 antidepressants Drugs 0.000 description 6
239000004480 active ingredient Substances 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
208000020401 Depressive disease Diseases 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
-1 cycloalkyl compound Chemical class 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
238000011260 co-administration Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008187 granular material Substances 0.000 description 1
241000411851 herbal medicine Species 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000002994 raw material Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Neurology (AREA)
Psychiatry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP58044528A 1982-03-22 1983-03-18 ジベンゾシクロヘプタジエンとコデルゴクリンを含有する薬学的組成物 Pending JPS58174317A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US36046382A	1982-03-22	1982-03-22
US360463		1994-12-21

Publications (1)

Publication Number	Publication Date
JPS58174317A true JPS58174317A (ja)	1983-10-13

Family

ID=23418055

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP58044528A Pending JPS58174317A (ja)	1982-03-22	1983-03-18	ジベンゾシクロヘプタジエンとコデルゴクリンを含有する薬学的組成物

Country Status (18)

Country	Link
JP (1)	JPS58174317A (fr)
AU (1)	AU1262283A (fr)
BE (1)	BE896170A (fr)
CA (1)	CA1197465A (fr)
CH (1)	CH652927A5 (fr)
DE (1)	DE3308855A1 (fr)
FR (1)	FR2527077B1 (fr)
GB (1)	GB2116843B (fr)
GR (1)	GR77165B (fr)
HU (1)	HU190714B (fr)
IL (1)	IL68184A (fr)
IT (1)	IT1163156B (fr)
NL (1)	NL8300986A (fr)
NZ (1)	NZ203632A (fr)
PH (1)	PH22086A (fr)
PT (1)	PT76417B (fr)
SE (1)	SE8301530L (fr)
ZA (1)	ZA832005B (fr)

1983
- 1983-03-10 CH CH1296/83A patent/CH652927A5/de not_active IP Right Cessation
- 1983-03-12 DE DE19833308855 patent/DE3308855A1/de not_active Withdrawn
- 1983-03-16 FR FR8304428A patent/FR2527077B1/fr not_active Expired
- 1983-03-16 BE BE1/10740A patent/BE896170A/fr not_active IP Right Cessation
- 1983-03-18 GR GR70832A patent/GR77165B/el unknown
- 1983-03-18 NL NL8300986A patent/NL8300986A/nl not_active Application Discontinuation
- 1983-03-18 JP JP58044528A patent/JPS58174317A/ja active Pending
- 1983-03-21 SE SE8301530A patent/SE8301530L/xx not_active Application Discontinuation
- 1983-03-21 HU HU83934A patent/HU190714B/hu unknown
- 1983-03-21 CA CA000424059A patent/CA1197465A/fr not_active Expired
- 1983-03-21 NZ NZ203632A patent/NZ203632A/en unknown
- 1983-03-21 PT PT76417A patent/PT76417B/pt unknown
- 1983-03-21 AU AU12622/83A patent/AU1262283A/en not_active Abandoned
- 1983-03-21 IT IT20186/83A patent/IT1163156B/it active
- 1983-03-21 IL IL68184A patent/IL68184A/xx unknown
- 1983-03-21 GB GB08307751A patent/GB2116843B/en not_active Expired
- 1983-03-22 ZA ZA832005A patent/ZA832005B/xx unknown
- 1983-06-01 PH PH28998A patent/PH22086A/en unknown

Also Published As

Publication number	Publication date
HU190714B (en)	1986-10-28
DE3308855A1 (de)	1983-09-29
IL68184A (en)	1986-04-29
IT8320186A0 (it)	1983-03-21
CH652927A5 (de)	1985-12-13
GB2116843A (en)	1983-10-05
ZA832005B (en)	1984-11-28
NL8300986A (nl)	1983-10-17
PT76417A (en)	1983-04-01
IT1163156B (it)	1987-04-08
CA1197465A (fr)	1985-12-03
SE8301530L (sv)	1983-09-23
BE896170A (fr)	1983-09-16
FR2527077A1 (fr)	1983-11-25
IL68184A0 (en)	1983-06-15
NZ203632A (en)	1986-09-10
GB8307751D0 (en)	1983-04-27
SE8301530D0 (sv)	1983-03-21
FR2527077B1 (fr)	1986-08-22
PT76417B (en)	1985-12-16
PH22086A (en)	1988-05-20
AU1262283A (en)	1983-09-29
GB2116843B (en)	1986-01-15
GR77165B (fr)	1984-09-10

Publication	Publication Date	Title
AU2003227516B2 (en)	2008-03-20	A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
DE3873879T2 (de)	1993-01-14	Nicht-sedative antihistaminica enthaltende husten-/schnupfenmittel.
JP4925074B2 (ja)	2012-04-25	ミルタザピンと１種以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物
US6191153B1 (en)	2001-02-20	Use of 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a pharmaceutical composition having an antidepressant activity
US20060030587A1 (en)	2006-02-09	Method of treating attention deficit disorders with d-threo methylphenidate
JP2904827B2 (ja)	1999-06-14	不安および不安抑うつ障害の処置に有用な医薬組成物の調製へのトリフルオロメチルフェニルテトラヒドロピリジンの使用
JPS59193821A (ja)	1984-11-02	抗不安薬としてのフルオキセチンの使用法
JPS6357405B2 (fr)	1988-11-11
US3954988A (en)	1976-05-04	Use of lisuride and physiologically acceptable salts thereof to achieve psychic energizer effects
US20090203727A1 (en)	2009-08-13	Novel pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion
IE904084A1 (en)	1991-05-22	Treatment of depression
US6372763B1 (en)	2002-04-16	Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (SSRI)
EP1615641A1 (fr)	2006-01-18	Combinaisons de paroxetine et de 2-(r)-(4-fluoro-2-methyl-phenyl)-4-(s)-((8as)-6-oxo-hexahydro-pyrrolo 1,2-a]-pyrazin-2-yl)-piperidine-1-acide carboxylique 1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide utilisees dans le traitement de la depression et/ou de l'anxiete
JPS58174317A (ja)	1983-10-13	ジベンゾシクロヘプタジエンとコデルゴクリンを含有する薬学的組成物
US4593031A (en)	1986-06-03	Method of treating depression
KR20010105418A (ko)	2001-11-28	기분 장애 치료용 오사네턴트
US3505451A (en)	1970-04-07	Compositions and methods for alleviating schizophrenia employing one of haloperidol,trifluperidol or an acid addition salt thereof and one of desipramine,imipramine and an acid addition salt thereof
CA2426492C (fr)	2006-10-03	Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer
EP0567498A1 (fr)	1993-11-03	Composition pharmaceutique contenant du granisetrone et du dexamethasone
WO1991012805A1 (fr)	1991-09-05	Methode de traitement par l'amperozide de la schizophrenie resistant aux traitements
JPS6116A (ja)	1986-01-06	有機化合物に関する改良
JPS6144816A (ja)	1986-03-04	組み合わせ生成物およびその調製方法
US3900566A (en)	1975-08-19	Pharmaceutical compositions containing the tert butyl ester of n-((1-carboxy-l-prolyl)-oxy)-succinimide and method of use
CA2558708A1 (fr)	2003-09-16	Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer
JPH0692304B2 (ja)	1994-11-16	向知性薬